Similar companies
Income Statement (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Revenue | 1.18B | 451.7% |
| Gross Profit | 1.16B | 500.9% |
| Cost of Revenue | 13M | 21% |
| Operating expense | 193M | 46.3% |
| Net Income | 867M | 1415.2% |
| EBITDA | 970M | 2169.8% |
Balance Sheet (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Total Assets | 2.66B | 55.7% |
| Total Liabilities | 2.84B | 1.4% |
| Shares Outstanding | 86M | 11.9% |
Cash Flow (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Cash from operations | 870M | 3000% |
| Cash from financing | 9.4M | 64.5% |
EPS
Financial Highlights for PTC Therapeutics in Q1 '25
PTC Therapeutics reported a revenue of 1.18B, which is a 451.7% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 1.16B, marking a 500.9% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 13M, a -21% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 193M, showing a -46.3% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 867M, showing a 1415.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 970M, showing a 2169.8% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for PTC Therapeutics with growth in revenue, gross profit, and net income.
